首页> Scientific reports> Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction.

Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction.

导出 LinkOut

翻译打印收藏纠错

第一作者： Ahmed,Al-Darraji

第一单位： Gill Heart and Vascular Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA.

作者： Ahmed,Al-Darraji ^[1] ; Renée R,Donahue ^[1] ; Himi,Tripathi ^[1] ; Hsuan,Peng ^[1] ; Bryana M,Levitan ^[1] ; Lakshman,Chelvarajan ^[1] ; Dalia,Haydar ^[2] ; Erhe,Gao ^[3] ; David,Henson ^[2] ; John C,Gensel ^[4] ; David J,Feola ^[2] ; Vincent J,Venditto ^[2] ; Ahmed,Abdel-Latif ^[5]

作者单位： Gill Heart and Vascular Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA. ^[1] College of Pharmacy, University of Kentucky, Lexington, KY, USA. ^[2] The Center for Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA. ^[3] Spinal Cord and Brain Injury Research Center, Department of Physiology, College of Medicine University of Kentucky, Lexington, USA. ^[4] Gill Heart and Vascular Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA. abdel-latif@uky.edu.;Division of Cardiology, University of Kentucky and the Lexington VAMC, 741 S. Limestone Street, BBSRB, Room 349, Lexington, KY, 40536-0509, USA. abdel-latif@uky.edu. ^[5]